Claritin syrup 1 mg / ml 60 ml

$5.23

Claritin syrup 1 mg / ml 60 ml

Quantity:

SKU: 818364624 Categories: , Tags: ,

Description

Composition
Active substance:
1 ml of syrup contains: 1 mg loratadine.
Excipients:
Propylene glycol, glycerol, citric acid monohydrate (alternatively – citric acid anhydrous), sodium benzoate, sucrose (granulated), artificial flavor (peach), purified water.
The clear colorless or yellowish syrup, containing no visible particles.
Description:
Claritin syrup – syrup from allergies for children and adults, the active substance is loratadine.
Looking for an antihistamine for treatment of allergy symptoms in children?
Claritin syrup-remedy for allergies, which can be given to children from 2 years old. One reception syrup capable for the day to alleviate the symptoms of allergic rhinitis, urticaria and allergic conjunctivitis: tearing,
allergic rhinitis, sneezing.
It is known that allergic rhinitis in children reduces (1) the overall index performance training.
Claritin helps to reduce the negative impact of allergic rhinitis on learning because it helps to eliminate symptoms and does not cause drowsiness (no more than 1.2% of cases).
(1). Vuurman E.F., van Veggel L.M. et al. Seasonal allergic rhinitis and antihistamine effects on childrens learning. Ann Allergy. 1993 Aug; 71 (2): 121-6. ”
Product form:
Syrup 1 mg / ml. 60 ml or 120 ml bottles in a dark glass, sealed with aluminum screw caps having a first opening and a ring gasket polyethylene or polypropylene screw cap, the ring having a first opening, the protection of children opening the bottle and a polyethylene gasket. 1 bottle complete with a plastic spoon or a graduated dosing syringe for 5 mL and instructions for use in a cardboard package.
Contraindications
Hypersensitivity to loratadine or any other component of the formulation.
Children under 2 years old.
During breastfeeding.
Patients deficient sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption – due to the presence of sucrose, a part of syrup.
Carefully:
Severe liver dysfunction.
Pregnancy (cm. “Apply during pregnancy and lactation”).
Dosage
1 mg / ml
Indications
Seasonal (hay fever) and perennial allergic rhinitis and allergic conjunctivitis – elimination of the symptoms associated with these diseases – sneezing, itching of the nasal mucosa, rhinorrhea, itching and burning sensation in the eyes, epiphora. Chronic idiopathic urticaria.
Interaction with other drugs
Eating does not affect the efficacy of the medicinal preparation Claritin.
Drug Claritin does not increase the action of alcohol on the central nervous system.
In a joint reception of loratadine with ketoconazole, erythromycin or cimetidine showed an increase in plasma concentrations of loratadine, but this increase was not clinically significant, including ECG data.
Overdose
Symptoms: drowsiness, tachycardia, headache.
In case of overdose should immediately consult a doctor.
Treatment: symptomatic and supportive therapy. Perhaps gastric lavage, adsorbents (activated pulverized coal with water).
Loratadine is not displayed by hemodialysis. After emergency treatment should be continued monitoring of the patient.
pharmachologic effect
Pharmacological group:
Antiallergic agent – H1-histamine receptor blocker.
Pharmacodynamics:
Loratadine – active substance medicament Claritin is a tricyclic compound with a strong antihistaminic activity and is a selective blocker of peripheral H1 histamine receptors. It has a rapid and prolonged antiallergic action. Valid – within 30 minutes after taking the drug Claritin inside. Antihistaminic effect reaches a maximum after 8-12 hours from onset of action and lasts more than 24 hours.
Loratadine does not penetrate the blood-brain barrier and does not affect the central nervous system. No clinically significant anticholinergic and sedative effects, ie It does not cause drowsiness and does not affect the speed of psychomotor reactions when used at the recommended doses. Priemlekarstvennogo Claritin preparation does not lead to a lengthening of QT interval on an electrocardiogram.
With prolonged treatment no clinically significant changes in vital signs, physical examination data, laboratory test results and ECG.
Loratadine has no significant selectivity for H2-histamine receptors. It does not inhibit the reuptake of norepinephrine and has virtually no effect on the cardiovascular system or pacemaker function.
Pharmacokinetics:
Loratadine is rapidly and well absorbed from the gastrointestinal tract. The time to reach maximum concentration (Tmax) of loratadine in plasma – 1-1.5 hours, while its active metabolite desloratadine – 1,5-3,7 hours. Food intake increases the time to reach maximum concentration (Tmax) of loratadine and desloratadine of about 1 hour, but no effect on drug efficacy. The maximum concentration (Cmax) of loratadine and desloratadine is independent of food intake. Patients with chronic kidney disease maximum concentration (Cmax) and area under the curve “concentration-time» (AUC) of loratadine and its active metabolite are increased as compared with patients with normal renal function. Half-lives of loratadine and its active metabolite, it does not differ from those of healthy patients. In patients with alcoholic liver disease Cmax and AUC values ​​of loratadine and its active metabolite is doubled in comparison with data rates in patients with normal liver function.
Loratadine has a high degree (97-99%) and its active metabolite – a moderate degree (73-76%) binding to plasma proteins.
Loratadine is metabolized in desloratadine by cytochrome P450 3A4 and to a lesser extent, of cytochrome P450 2D6. Eliminated via the kidneys (approximately 40% of an oral dose), and through the intestine (about 42% of an oral dose) for more than 10 days, preferably in the form of conjugated metabolites. Approximately 27% of an oral dose is excreted via the kidneys within 24 hours after receiving the medicament. Less than 1% of the active substance eliminated via the kidneys in unchanged form within 24 hours after receiving the medicament.
The bioavailability of loratadine and its active metabolite is dose-dependent.
The pharmacokinetic profile of loratadine and its active metabolite in adults and elderly healthy volunteers were comparable.
The half life of loratadine ranges from 3 to 20 hours (mean 8.4 hours) and desloratadine – from 8.8 to 92 hours (mean 28 hours); elderly patients, respectively, from 6.7 to 37 hours (mean 18.2 hours) and from 11 to 39 hours (mean 17.5 hours). The half-life is increased in alcoholic liver injury (depending on the severity of the disease) and does not change in the presence of chronic renal insufficiency.
Hemodialysis patients with chronic renal failure has no effect on the pharmacokinetics of loratadine and its active metabolite.
Pregnancy and breast-feeding
Safety of application of loratadine during pregnancy has not been established. The use of drug Claritin during pregnancy is possible only after consultation with your doctor if the expected benefit to the mother outweighs the potential risk to the fetus.
Loratadine and its active metabolite are allocated in breast milk, so the appointment of the drug during lactation should decide the issue of termination of breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
In clinical studies involving children aged from 2 to 12 years who were taking medication Claritin more frequently than with placebo ( “dummy”): headache (2.7%), nervousness (2.3%), fatigue ( 1 %).
In clinical trials involving adults adverse events were observed more frequently than with placebo, occurred in 2% of patients taking the drug Claritin. In adults, the application Claritin medicament more often than in the placebo group were observed headache (0.6%), somnolence (1.2%), increased appetite (0.5%) and insomnia (0.1%). In addition, in the post-marketing period there were very rare reports (
special instructions
Medication Claritin should be discontinued 48 hours before skin tests since antihistamines drugs can distort the results of the diagnostic study.
Effects on ability to drive vehicles and management mechanisms:
Revealed no adverse effects of the drug Claritin drug on the ability to drive a car or other activities that require full attention.
However, in very rare cases, some patients experience drowsiness while taking the drug Claritin, which may affect their ability to drive and use machines.
Storage conditions
At a temperature above 25 degrees Celsius. Keep out of the reach of children.
Dosing and Administration
Inside, regardless of mealtime.
For adults, including the elderly and adolescents over 12 years are recommended to take the drug Claritin 10 mg (2 teaspoons (10 ml) of syrup) 1 time per day.
In applying the drug in elderly patients and in patients with the presence of chronic renal insufficiency dose adjustment is required.
Children aged 2 to 12 years, the dose of the drug is recommended to assign Claritin depending on body weight – 30 kg, and less than – 5 mg (1 teaspoon (5ml) of syrup) 1 times a day; – 30 kg – 10 mg (2 teaspoons (10 ml) of syrup) 1 time per day.
Adults and children with severe hepatic impairment initial dose should be: the body weight of 30 kg, and less than – 5 mg (1 teaspoon (5ml) of syrup) a day, with a body weight of over 30 kg – 10 mg (2 teaspoons ( 10 ml) syrup) every other day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Claritin

There are no reviews yet.

Add your review